A detailed history of Aton Ra Partners transactions in Exact Sciences Corp stock. As of the latest transaction made, Aton Ra Partners holds 9,013 shares of EXAS stock, worth $523,745. This represents 1.33% of its overall portfolio holdings.

Number of Shares
9,013
Previous 9,859 8.58%
Holding current value
$523,745
Previous $672,000 0.89%
% of portfolio
1.33%
Previous 1.41%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

SELL
$59.06 - $75.72 $49,964 - $64,059
-846 Reduced 8.58%
9,013 $666,000
Q3 2023

Oct 25, 2023

SELL
$65.94 - $99.04 $16,880 - $25,354
-256 Reduced 2.53%
9,859 $672,000
Q2 2023

Jul 18, 2023

SELL
$62.68 - $95.05 $88,692 - $134,495
-1,415 Reduced 12.27%
10,115 $949,000
Q1 2023

May 05, 2023

SELL
$47.19 - $70.77 $76,542 - $114,788
-1,622 Reduced 12.33%
11,530 $781,000
Q4 2022

Feb 02, 2023

BUY
$30.35 - $53.15 $22,398 - $39,224
738 Added 5.94%
13,152 $651,000
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $103,902 - $160,452
3,250 Added 35.46%
12,414 $403,000
Q2 2022

Aug 15, 2022

SELL
$35.61 - $76.23 $34,612 - $74,095
-972 Reduced 9.59%
9,164 $361,000
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $97,506 - $139,822
-1,694 Reduced 14.32%
10,136 $709,000
Q4 2021

Feb 14, 2022

BUY
$72.5 - $100.68 $42,630 - $59,199
588 Added 5.23%
11,830 $921,000
Q3 2021

Nov 15, 2021

BUY
$90.24 - $124.05 $132,923 - $182,725
1,473 Added 15.08%
11,242 $1.07 Million
Q2 2021

Aug 12, 2021

BUY
$93.66 - $139.27 $10,208 - $15,180
109 Added 1.13%
9,769 $1.21 Million
Q1 2021

May 17, 2021

BUY
$116.57 - $155.01 $1.13 Million - $1.5 Million
9,660 New
9,660 $1.27 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.3B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Aton Ra Partners Portfolio

Follow Aton Ra Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.